AbbVie Pounces On Chance To Buy Revenues In $63bn Mega-Deal For Allergan
Executive Summary
AbbVie will gain the $3.58bn Botox business, a women's health franchise and gastrointestinal products in an opportunistic acquisition intended to reduce the company's dependence on Humira.
You may also be interested in...
Lyndra’s Series E Cash Expected To Get Weekly Risperidone To An FDA Filing
Working for years to develop weekly or monthly oral drugs, Lyndra raises $101m and licenses commercial rights in six nations to Sun Pharma in a deal getting its lead product closer to the finish line.
Novartis Eyes Leaner Ophthalmic Business In Xiidra Deal With Bausch + Lomb
The Swiss drug maker said it would sell the underperforming dry eye drug plus pipeline assets and rights to a delivery device for $2.5bn, which for Bausch + Lomb means a bigger presence in the space.
Bausch + Lomb Turns To Familiar Face As CEO, Brent Saunders
Saunders will oversee the consumer health, pharma and medtech eye health and vision care specialist, returning to where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.